Gilead Sciences, Inc. (GILD) Covered Calls
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. By 2026, Gilead has successfully transitioned from a pure-play virology firm to a diversified leader in HIV, oncology, and liver diseases. Under CEO Daniel O’Day, the company is scaling its twice-yearly injectable Yeztugo (lenacapavir) and expanding its antibody-drug conjugate (ADC) portfolio through Trodelvy.
You can sell covered calls on Gilead Sciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GILD (prices last updated Wed 4:16 PM ET):
| Gilead Sciences, Inc. (GILD) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 146.00 | -2.56 | 145.16 | 148.48 | 4.8M | 22 | 184 |
| Covered Calls For Gilead Sciences, Inc. (GILD) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 146 | 2.33 | 146.15 | 0.5% | 18.2% | |
| Apr 17 | 145 | 5.75 | 142.73 | 2.2% | 21.1% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Gilead operates a highly profitable franchise centered on antiviral leadership and a rapidly maturing oncology pipeline. In 2026, the company achieved record margins following a strategic manufacturing and pricing agreement with the U.S. government. Their primary segments include:
- HIV Franchise: The company's primary revenue driver, led by Biktarvy and the 2025 approval of Yeztugo (lenacapavir), the world’s first twice-yearly injectable for HIV prevention (PrEP).
- Oncology & Cell Therapy: A high-growth segment featuring Trodelvy for breast and lung cancer, and its Kite Pharma subsidiary, which leads the CAR-T market with Yescarta and Tecartus.
- Liver Disease & COVID-19: Comprising leading treatments for Hepatitis C (Epclusa), Hepatitis B, and the antiviral Veklury (remdesivir), which remains a standard of care for hospitalized COVID-19 patients.
Competitive Landscape
Gilead faces intense competition from global pharmaceutical giants and innovative biotech firms. In the HIV market, its most direct rival is ViiV Healthcare (a joint venture of GSK and Pfizer). In oncology and cell therapy, it competes with Bristol Myers Squibb, AstraZeneca, and Merck, the latter of which partners with Gilead on long-acting oral HIV treatments. For diversified biotech exposure, it is frequently compared to Amgen and Regeneron. As a "Dividend King" in the making, Gilead’s strong cash flow and 2.2% yield provide a competitive moat against smaller, pre-profit biotech challengers.
Strategic Outlook and Innovation
The 2026 strategic roadmap for Gilead is defined by "The Precision Oncology Pivot." Following its 2026 licensing deal with Repare Therapeutics, Gilead is utilizing Generative AI via the Genesis Therapeutics platform to discover small molecules for "undruggable" cancer targets. A major focus is TrumpRx.gov integration; under a late-2025 federal agreement, Gilead provides discounted access to its Hepatitis C and HIV medicines in exchange for a three-year exemption from specific pharmaceutical tariffs. In 2026, the company reached a 35% non-GAAP operating margin, fueled by the lower-cost production of its "Purpose" clinical program. With a robust $32 billion five-year U.S. investment plan, Gilead aims to dominate the "long-acting" therapeutic era, shifting the patient experience from daily pills to seasonal injections while maintaining its position as a top-tier cash-flow machine for shareholders.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | FLY covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | S covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | USO covered calls | |
Want more examples? GIL Covered Calls | GILT Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
